Epstein-Barr virus-driven gene therapy for EBV-related lymphomas

Nature Medicine

Volumn 2, Issue 12, 1996, Pages 1379-1382

  Franken, Michael ^a,d   Estabrooks, Anita ^a   Cavacini, Lisa ^a   Sherburne, Brad ^a   Wang, Fred ^b   Scadden, David T ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE THERAPY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES; BURKITT LYMPHOMA; CINNAMATES; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GANCICLOVIR; GENE THERAPY; HERPESVIRUS 4, HUMAN; HUMANS; HYGROMYCIN B; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS (GENETICS); RECOMBINANT FUSION PROTEINS; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

ANIMALIA; HUMAN HERPESVIRUS 4;

EID: 0029851125     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1296-1379     Document Type: Article

References (24)

1. Rooney, C.M. et al. Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes. J. Virol. 66, 496-504 (1992).
2. Wang, F., Kikutani, H., Tsang, S., Kishimoto, T. & Kieff, E. Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element. J. Virol. 65, 4101-4106 (1991).
3. Ghosh, D. & Kieff, E. cis-Acting regulatory elements near the Epstein-Barr virus latent-infection membrane protein transcriptional start site. J. Virol. 64, 1855-1858 (1990).
4. Zimber-Strobl, U. et al. Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J. Virol. 65, 415-423 (1991).
5. Grossman, S.R., Johannsen, E., Tong, X., Yalamanchili, R. & Kieff, E. The Epstein-Batr virus nuclear antigen 2 transactivator is directed to response elements by the Jκ recombination signal binding protein. Proc. Natl. Acad. Sci. USA 91, 7568-7572 (1994).
6. Henkel, T., Ling, P.D., Hayward, S.D. & Peterson, M.G. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science 265, 92-95 (1994).
7. Calendar, A. et al. Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc. Natl. Acad. Sci. USA 84, 8060-8064 (1987).
8. Deisseroth, A.B., Kavanagh, J. & Champlin, R. Use of safety-modified retroviruses to introduce chemotherapy during the therapy of ovarian cancer: A pilot trial. Hum. Gene Ther. 5, 1507-1522 (1994).
9. Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543 (1993).
10. Shewach, D.S. et al. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells. Cancer Gene Ther. 1, 107-112 (1994).
11. Han, X., Kasahara, N., & Kan, Y.W. Ligand-directed retroviral targeting of human breast cancer cells. Proc. Natl. Acad. Sci. USA 92, 9747-9751 (1995).
12. Huber, B.E., Richards, C.A. & Krenitsky, T.A. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA 88, 8039-8043 (1991).
13. Vile, R.G. & Hart, I.R. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53, 962-967 (1993).
14. Rea, D. et al. Epstein-Barr virus latent and replicative gene expression in posttransplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas. French Study Group of Pathology for HIV-associated Tumors. Ann. Oncol. 5 (Suppl. 1), S113-S116 (1994).
15. Knowles, D.M. Biologic aspects of AIDS-associated non-Hodgkin's lymphoma. Curr. Opin. Oncol. 5, 845-851 (1993).
16. Hamilton-Dutoit, S.J. et al. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma: Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am. J. Pathol. 143, 1072-1085 (1993).
17. Bashir, R., Luka, J., Cheloha, K., Chamberlain, M. & Hochberg, F. Expression of Epstein-Barr virus proteins in primary CNS lymphoma in AIDS patients. Neurology 43, 2358-2362 (1993).
18. Carbone, A., Tirelli, U., Gloghini, A., Volpe, R. & Boiocchi, M. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J. Clin. Oncol. 11, 1674-1681 (1993).
19. daCosta, T.L., Jen, J., He, T.C., Chen, T.A. & Kinzler, K.W. Converting cancer genes into killer genes. Proc. Natl. Acad. Sci. USA 93, 4192-4196 (1996).
20. Hasegawa, R., Emi, N. & Shimokata, K. Retroviral transfer of HSV1-TK gene into human lung cancer cell line. J. Mol. Med. 73, 107-112 (1995).
21. Culver, K.W. et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552 (1992).
22. Hurford, R.K., Dranoff, G., Mulligan, R.C. & Tepper, R.I. Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nature Genet. 10, 430-435 (1995).
23. Oshiro, E.M. et al. Toxicity studies and distribution dynamics of retroviral vectors following intrathecal administration of retroviral vector-producer cells. Cancer Gene Ther. 2, 87-95 (1995).
24. Lupton, S.D., Brunton, L.L., Kalberg, V.A. & Overell, R.W. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol. Cell. Biol. 11, 3374-3378 (1991).